Imfinzi (durvalumab) [product information]. EMA.

Regulatory approval published by the European Medicines Agency.

Citation

AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised August 2024. Accessed August 24, 2024.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on >= 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.	1
IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.	1
IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).	2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab
Sensitivity (+)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
Sensitivity (+)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel
Sensitivity (+)	pMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Olaparib, Paclitaxel